Van ECK Associates Corp lowered its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 17.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,923 shares of the biotechnology company’s stock after selling 9,304 shares during the period. Van ECK Associates Corp owned 0.10% of bluebird bio worth $4,719,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. raised its position in shares of bluebird bio by 33.4% during the second quarter. UBS Asset Management Americas Inc. now owns 236,359 shares of the biotechnology company’s stock valued at $24,830,000 after buying an additional 59,116 shares during the last quarter. Quantitative Investment Management LLC raised its position in shares of bluebird bio by 1,193.8% during the second quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock valued at $11,009,000 after buying an additional 96,700 shares during the last quarter. Nicholas Investment Partners LP raised its position in shares of bluebird bio by 36.1% during the second quarter. Nicholas Investment Partners LP now owns 50,183 shares of the biotechnology company’s stock valued at $5,273,000 after buying an additional 13,310 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of bluebird bio by 14.3% during the second quarter. New York State Common Retirement Fund now owns 148,254 shares of the biotechnology company’s stock valued at $15,574,000 after buying an additional 18,545 shares during the last quarter. Finally, Sivik Global Healthcare LLC raised its position in shares of bluebird bio by 7.9% during the second quarter. Sivik Global Healthcare LLC now owns 15,000 shares of the biotechnology company’s stock valued at $1,576,000 after buying an additional 1,100 shares during the last quarter.

In other bluebird bio news, insider Eric Sullivan sold 6,787 shares of the company’s stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $108.96, for a total value of $739,511.52. Following the completion of the sale, the insider now directly owns 8,466 shares in the company, valued at approximately $922,455.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Nick Leschly sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $108.05, for a total value of $2,701,250.00. Following the completion of the sale, the insider now owns 360,656 shares of the company’s stock, valued at $38,968,880.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 165,616 shares of company stock valued at $19,447,660. 3.90% of the stock is owned by company insiders.

bluebird bio, Inc. (BLUE) opened at 128.75 on Friday. The firm’s 50-day moving average is $108.37 and its 200 day moving average is $97.10. The stock’s market capitalization is $5.87 billion. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $136.85.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The company had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The firm’s quarterly revenue was up 977.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.59) earnings per share. Equities analysts anticipate that bluebird bio, Inc. will post ($6.84) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/24/bluebird-bio-inc-blue-stake-lessened-by-van-eck-associates-corp.html.

Several equities research analysts have recently issued reports on the stock. Barclays PLC assumed coverage on shares of bluebird bio in a research report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 price objective on the stock. Wells Fargo & Company reiterated an “outperform” rating and set a $158.00 price objective (up previously from $134.00) on shares of bluebird bio in a research report on Tuesday, September 5th. Wedbush reiterated an “outperform” rating and set a $135.00 price objective (up previously from $121.00) on shares of bluebird bio in a research report on Friday, September 1st. Cowen and Company reiterated an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Finally, Evercore ISI assumed coverage on shares of bluebird bio in a research report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $107.86.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.